Form 4: Oncotelic Therapeutics CEO Increases Stake in Company Through Open Market Purchases
SEC Form 4 Filing
Oncotelic Therapeutics' CEO, Vuong Trieu, has increased his holdings in the company by purchasing 346,844 shares of common stock on the open market between January 29 and January 31, 2025.
Summary
- Vuong Trieu, the Chairman and CEO of Oncotelic Therapeutics, Inc., has acquired additional shares of the company's common stock.
- Between January 29 and January 31, 2025, Dr. Trieu purchased a total of 346,844 shares on the open market.
- The purchase price for these shares was $0.028 per share.
- Following these transactions, Dr. Trieu directly owns 93,189,560 shares of Oncotelic Therapeutics.
- He also indirectly owns 16,780,384 shares through Autotelic, Inc. and 6,872,529 shares through his spouse.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's increased investment suggests confidence, but the document is primarily a regulatory filing of stock transactions.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's important to consider the overall context of the company's performance and industry trends.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Dr. Trieu purchased 183,066 shares of Oncotelic Therapeutics, Inc. |
| 01/30/2025 | Dr. Trieu purchased 100,003 shares of Oncotelic Therapeutics, Inc. |
| 01/31/2025 | Dr. Trieu purchased 63,775 shares of Oncotelic Therapeutics, Inc. |
| 01/31/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.